Pascal Biosciences Inc
XTSX:PAS
Pascal Biosciences Inc
Total Current Assets
Pascal Biosciences Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pascal Biosciences Inc
XTSX:PAS
|
Total Current Assets
CA$18.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Current Assets
CA$84.3m
|
CAGR 3-Years
61%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Current Assets
$438.7m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
35%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Current Assets
$480.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Current Assets
CA$34.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Current Assets
$201.4m
|
CAGR 3-Years
107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pascal Biosciences Inc
Glance View
Pascal Biosciences, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-03-16. The firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The firm operates in the segment of biotechnology research and development. The firm is focused on developing cannabinoid-based and targeted therapeutics to fight cancer. Its cannabinoid portfolio includes PAS-403, PAS-393 and Cannabinoid for corona virus disease-2019 (COVID-19). Its PAS-403 is a small molecule therapeutics for the treatment of glioblastoma. Its PAS-393, is an immune-stimulatory cannabinoid used in combination with checkpoint inhibitor therapy to treat multiple cancers. In addition, it is developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.
See Also
What is Pascal Biosciences Inc's Total Current Assets?
Total Current Assets
18.8k
CAD
Based on the financial report for Nov 30, 2022, Pascal Biosciences Inc's Total Current Assets amounts to 18.8k CAD.
What is Pascal Biosciences Inc's Total Current Assets growth rate?
Total Current Assets CAGR 1Y
-87%
Over the last year, the Total Current Assets growth was -87%.
